Fusion AntibodiesLSE:FAB -2.17%32 Current Ratio is 1.80 as of Sep. 2025, which is 47% below its 10-year median of 3.40. GuruFocus rates LSE:FAB with a GF Score™ of 32/100 and a GF Value™ of £0.04 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,412 Biotechnology companies, Fusion Antibodies ranks worse than 71.6% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Fusion Antibodies's current ratio for the quarter that ended in Sep. 2025 was 1.80.
Fusion Antibodies has a current ratio of 1.80. It generally indicates good short-term financial strength.
The historical rank and industry rank for Fusion Antibodies's Current Ratio or its related term are showing as below:
LSE:FAB'
s Current Ratio Range Over the Past 10 Years
Min: 1.77 Med: 3.4 Max: 9.66
Current: 1.8
During the past 11 years, Fusion Antibodies's highest Current Ratio was 9.66. The lowest was 1.77. And the median was 3.40.
LSE:FAB's Current Ratio is ranked worse than 71.6% of 1412
companies
in the Biotechnology industry
Industry Median: 3.89
vs LSE:FAB: 1.80
Fusion Antibodies (LSE:FAB) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Fusion Antibodies Current Ratio Related Terms
Fusion Antibodies Current Ratio Historical Data
* Premium members only.
The historical data trend for Fusion Antibodies's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:FAB vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Fusion Antibodies's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fusion Antibodies Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fusion Antibodies's Current Ratio distribution charts can be found below:
* The bar in red indicates where Fusion Antibodies's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fusion Antibodies (LSE:FAB) has a Current Ratio of 1.80 as of Sep. 2025. This is 47% below median its historical median of 3.40. Over the past decade, Fusion Antibodies' Current Ratio has ranged from 1.77 to 9.66. According to the industry distribution chart, Fusion Antibodies ranks #1011 out of 1412 companies in the Biotechnology industry, placing it in the top 71.6%.
Is Fusion Antibodies' Current Ratio too high?
Fusion Antibodies' current Current Ratio of 1.80 is 47% below median its 10-year median of 3.40. Over the past 10 years, this metric has ranged from a low of 1.77 to a high of 9.66. The Biotechnology industry median Current Ratio is 3.89. Fusion Antibodies' value of 1.80 is 53.7% below this industry median. Based on the distribution chart, Fusion Antibodies ranks #1011 out of 1412 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Fusion Antibodies has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fusion Antibodies' Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Fusion Antibodies ranks #1011 out of 1412 companies for Current Ratio. This places Fusion Antibodies in the lower half of its industry. The industry median Current Ratio is 3.89. Fusion Antibodies' value of 1.80 is 53.7% below this benchmark. Historically, Fusion Antibodies' own Current Ratio has ranged from 1.77 to 9.66 over the past decade. While the company's 10-year median is 3.40 vs. the industry median of 3.89, Fusion Antibodies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fusion Antibodies's current Current Ratio of 1.80 is 53.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fusion Antibodies's current Current Ratio is 1.80, which is 47% below median its own 10-year median of 3.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fusion Antibodies stock overvalued right now?
Based on GuruFocus' analysis, Fusion Antibodies (LSE:FAB) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.04, compared to a current price of £0.11 — trading 181.3% above its estimated fair value. The current Current Ratio is 1.80, which is 47% below median its 10-year median of 3.40 and 53.7% below the Biotechnology industry median of 3.89. Fusion Antibodies' overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Fusion Antibodies (LSE:FAB), the current Current Ratio is 1.80 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fusion Antibodies (LSE:FAB) Overvalued in 2026?
Based on GuruFocus' analysis, Fusion Antibodies stock appears to be overvalued.
The current stock price of £0.11 is trading 181.3% above its estimated GF Value™ of £0.04.
GuruFocus considers Fusion Antibodies to be Significantly Overvalued.
Key valuation signals for LSE:FAB:
Current Ratio: 1.80 (47% below median its 10-year median of 3.40)
GF Value™: £0.04 vs. price of £0.11 (181.3% above fair value)
Industry Position: 53.7% below the Biotechnology median (#1011 of 1412)
No single metric tells the full story. See the LSE:FAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fusion Antibodies PLC is a Contract Research Organisation (CRO) providing antibody identification, engineering, and expression services for the discovery and development of antibodies for human and veterinary therapeutics, as well as for diagnostics. Its customers are pharmaceutical, biotech, veterinary, diagnostic, and life science research companies. The company's three core service areas include: Discovery (identification, screening, and sequencing of novel antibodies); Engineering (optimising the performance of antibodies); and Supply (production and purification of antibodies for further development). Geographically company generates the majority of its revenue from North America and the Rest of the World, followed by the United Kingdom and the Rest of Europe.
32GF Score
Get the complete analysis for LSE:FAB
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:FAB has been successfully added to your 
